Tumor markers and molecular biological markers in gynecologic malignancies
- 1 February 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 13 (1) , 31-39
- https://doi.org/10.1097/00001703-200102000-00005
Abstract
Gynecologic oncology is a rapidly growing field due to constant advances in immunohistochemistry and molecular biology. This review serves as an overview of new studies promoting the use of tumor markers and molecular biological prognostic factors in malignancies affecting women. The majority of studies focus on either endometrial or ovarian carcinoma. Other gynecologic malignancies (cervical, vulvar, and vaginal carcinoma) have a much smaller representation in the world literature. Multiple new markers were examined over the last year. We conclude that although some markers show promise as potential new consensus prognostic indicators, more work is needed to confirm results and clarify any existing discrepancies.This publication has 58 references indexed in Scilit:
- p53 and bcl-2 in Epithelial Ovarian Carcinoma: Their Value as Prognostic Indicators at a Median Follow-up of 60 MonthsGynecologic Oncology, 2000
- Reduction of BRCA1 Expression in Sporadic Ovarian CancerGynecologic Oncology, 2000
- MIB-1 in Endometrial Carcinoma: Prognostic Significance with 5-Year Follow-UpGynecologic Oncology, 1999
- Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of Stage I endometrial carcinomaCancer, 1999
- The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cellsCancer, 1999
- Prognostic Significance of DNA Ploidy in Endometrial CancerGynecologic Oncology, 1999
- Product ReviewPublished by Wolters Kluwer Health ,1999
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- Quantification of p53 in Epithelial Ovarian CancerGynecologic Oncology, 1997
- CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990sAmerican Journal of Obstetrics and Gynecology, 1996